Kazakh National Agrarian University

This early-stage study tests a new vaccine called PollenVax for people with moderate to severe mugwort pollen allergy. The main goal is to see if the vaccine is safe and tolerable in 30 adults aged 18 to 65. Participants receive four shots of either the vaccine or a placebo, and …